Retrospective Evaluation of the Results of Low-Dose Intravenous Thrombolytic Therapy in Acute Ischemic Stroke

Objectives: This study aimed to investigate the clinical data of patients with acute ischemic stroke who received low-dose intravenous (IV) thrombolytic therapy (0.9 mg/kg; maximum 50 mg) for various reasons, compare the obtained results with those of patients who received standard-dose thrombolytic therapy, and discuss them in light of the literature.
Methods: Patients who received IV thrombolytic therapy within 4.5 h of symptom onset between January 2015 and June 2018 were retrospectively reviewed. Patients were divided into the low-dose group (0.9 mg/kg; max. 50 mg) and the standard-dose group (0.9 mg/kg; max 90 mg) according to the thrombolytic therapy dose, after which demographic data and clinical results were analyzed.
Results: A total of 109 patients receiving thrombolytic therapy (19 patients in the low-dose group and 90 patients in the standard-dose group) were included in the study. There was no significant difference between the two groups in terms of good outcome rates (47.4% vs. 52.2%). There was no statistically significant difference in terms of symptomatic and asymptomatic intracerebral hemorrhage rates.
Conclusion: Our study showed similar efficacy and safety for low-dose IV thrombolytic therapy compared with standard-dose IV thrombolytic therapy administered within 4.5 h of symptom onset in patients with acute ischemic stroke.

Akut Ýskemik Ýnmede Düþük Doz Ýntravenöz Trombolitik Tedavi Sonuçlarýnýn Retrospektif Deðerlendirilmesi

Amaç: Çalýþmada, akut iskemik inmede düþük doz (0,9 mg/kg; maksimum 50 mg/kg) trombolitik tedavi uygulanan hastalarýn klinik verilerinin incelenmesi, sonuçlarýn standart doz trombolitik tedavi uygulanan hastalarla karþýlaþtýrýlmasý amaçlandý.
Yöntem: Ocak 2015 ve Haziran 2018 tarihleri arasýnda semptom baþlangýcýndan sonraki 4,5 içerisinde intravenöz trombolitik tedavi uygulanmýþ hastalar retrospektif olarak incelendi. Uygulanan trombolitik tedavi dozuna göre hastalar düþük doz grubu (0,9 mg/kg; maksimum 50 mg/kg) ve standart doz grubu (0,9 mg / kg; maksimum 90 mg/kg) olarak ayrýlarak demografik veriler ve klinik sonuçlar analiz edildi.
Bulgular: Trombolitik tedavi uygulanan toplam 109 hasta çalýþmaya dahil edildi (düþük doz grubunda 19 hasta ve standart doz grubunda 90 hasta). Her iki grupta da iyi sonuç oraný arasýnda anlamlý bir fark yoktu (%47,4'e karþýlýk %52,2). Semptomatik ve asemptomatik intraserebral kanama oranlarý arasýnda istatistiksel anlamlý fark saptanmadý.
Sonuç: Çalýþmamýz akut iskemik inmeli hastalarda semptom baþlangýcýndan itibaren ilk 4,5 saat içerisinde uygulanan standart doz trombolitik tedaviyle kýyaslandýðýnda düþük doz intravenöz trombolitik tedavinin benzer etkinlik ve güvenilirliðe sahip olduðunu göstermektedir. (SETB-2022-05-133)